Details of the Drug Combinations

General Information of This Drug (ID: DMMP51W)

• Drug Name: Sparsentan (DMMP51W)
• Synonyms: Sparsentan; RE-021; 254740-64-2; UNII-9242RO5URM; PS433540; PS-433540; CHEMBL539423; 9242RO5URM; BMS-346567; retrophin; Sparsentan [USAN]; compound 7 [PMID 15634011]; PS 33540; Sparsentan (RE-021); Sparsentan(PS433540); SCHEMBL535109; GTPL8448; BCP23969; BDBM50175523; SB16876; DB12548; CS-7947; DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors); HY-17621; L023324; 4'-((2-butyl-4-oxo-1,3-diazaspiro[44]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide; RE-021

Indication

IgA nephropathy; ICD 11: MF8Y; Status: Approved [1]; Focal segmental glomerulosclerosis; ICD 11: MF8Y; Status: Phase 3 [2]; Hypertension; ICD 11: BA00-BA04; Status: Phase 2 [3]; Myocardial infarction; ICD 11: BA41-BA43; Status: Phase 2 [4]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dapagliflozin + Sparsentan	DCU77WL	Dapagliflozin	Immunoglobulin A Nephropathy	[5]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216403.
• [2] ClinicalTrials.gov (NCT03493685) Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00635232) A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension. U.S. National Institutes of Health.
• [4] Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005 Jan 13;48(1):171-9.
• [5] ClinicalTrials.gov (NCT03762850) A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy